# AVZO-023

Source: https://onco.cc/drugs/avzo-023/  
OnCo record `avzo-023` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer.

## Summary

AVZO-023 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Avenzo Therapeutics, Inc., in metastatic cancer. Described in the registry record as a avzo-023 is an oral selective cdk4 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AVZO-023
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a avzo-023 is an oral selective cdk4 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of AVZO-023: https://clinicaltrials.gov/search?intr=AVZO-023

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/)
- trials: [ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct06998407/)

---
JSON: https://onco.cc/api/v1/entities/avzo-023.json